
Orphion Therapeutics: Developing innovative gene therapies for rare genetic disorders.
Orphion Therapeutics, a pioneering gene therapy developer, is dedicated to creating innovative treatments for rare and serious genetic disorders. The company was founded by an experienced executive management team with a strong background in drug development. Orphion's core mission is to advance gene therapy solutions that can significantly improve the lives of patients suffering from these debilitating conditions. Their market focus is on addressing unmet medical needs within the realm of rare genetic diseases.
The company is supported by a network of respected healthcare investors, which underscores its credibility and potential in the biotech industry. Orphion Therapeutics has made notable strides in the field of gene therapy, leveraging cutting-edge technologies and research to develop their treatments. The impact of their work is profound, offering hope and potential cures for conditions that currently have limited or no treatment options.

Orphan Star Therapeutics

Orphinic Scientific
orphinic.com

Orbital Therapeutics

Orbus Therapeutics

Jaguar Gene Therapy

Intergalactic Therapeutics

Aurion Biotech
aurionbiotech.com

Phoenicis

Orna Therapeutics

Forge Biologics
forgebiologics.com

Orpro Therapeutics

GeneVentiv Therapeutics
geneventiv.com

Remedium Bio
remedium-bio.com
Orion BioScience

Orig3N
orig3n.com
Companies similar to Orphion Therapeutics include Orphan Star Therapeutics, Orphinic Scientific, Orbital Therapeutics and Orbus Therapeutics.
Orphion Therapeutics was founded in 2020.
Orphion Therapeutics' headquarters is located in Great Neck, NY, US.
Orphion Therapeutics' most recent funding round was for $5.3M (USD) in November 2020.
As of Nov 17, 2020, Orphion Therapeutics has raised a total of $5.3M (USD).
Orphion Therapeutics has 6 employees as of Feb 5, 2024.